Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781652 | 0.85 | DPP4 (0.43) | ALDH1A1MAPK1SMN1; SMN2DHODHKDM4E | |
| SCHEMBL596184 | 0.85 | CYP3A4 (0.50) | ALDH1A1MAPK1SMN1; SMN2DHODHCYP3A4 | |
| SCHEMBL15571512 | 0.84 | POLB (0.39) | ALDH1A1MAPK1SMN1; SMN2DHODHPOLB | |
| SCHEMBL9737304 | 0.83 | ALDH1A1 (0.52) | ALDH1A1MAPK1SMN1; SMN2DHODHCYP3A4 | |
| SCHEMBL3713227 | 0.82 | POLB (0.50) | ALDH1A1MAPK1SMN1; SMN2DHODHCYP3A4 | |
| SCHEMBL31204508 | 0.82 | POLB (0.50) | ALDH1A1MAPK1SMN1; SMN2DHODHCYP3A4 | |
| SCHEMBL612875 | 0.79 | CYP3A4 (0.47) | ALDH1A1SMN1; SMN2CYP3A4ACHEPOLB | |
| SCHEMBL3765067 | 0.79 | SMN1; SMN2 (0.52) | ALDH1A1MAPK1SMN1; SMN2CYP3A4ACHE | |
| SCHEMBL12760104 | 0.78 | CYP3A4 (0.41) | ALDH1A1MAPK1SMN1; SMN2DHODHCYP3A4 | |
| SCHEMBL25329987 | 0.78 | CYP3A4 (0.64) | ALDH1A1MAPK1SMN1; SMN2DHODHCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724436-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| WO-2024259017-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4416141-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| CN-101039907-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | ALDH1A1 3447/4885MAPK1 4529/4885SMN1; SMN2 302/4885 |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ALDH1A1 575/4885MAPK1 1375/4885SMN1; SMN2 4692/4885 |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | ALDH1A1 1757/4885MAPK1 2286/4885SMN1; SMN2 3741/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | ALDH1A1 1582/4885MAPK1 1535/4885SMN1; SMN2 4028/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ALDH1A1 468/4885MAPK1 1894/4885SMN1; SMN2 4606/4885 |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM2 | ALDH1A1 2271/4885MAPK1 2346/4885SMN1; SMN2 2179/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | ALDH1A1 3818/4885MAPK1 1204/4885SMN1; SMN2 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.